Diamyd Medical has announced the acquisition of the property in Umeå where production of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd is being established.
“The manufacturing facility is a crucial investment for the future and the acquisition gives us further opportunities to scale up and expand our manufacturing activities,” says Ulf Hannelius, CEO of Diamyd Medical.
Read more: Diamyd Medical raises 150 million SEK
SEK 24.5 million
The property is acquired for a purchase price of SEK 24.5 million and comprises approximately 20,000 square feet including the 10,000 square feet Diamyd Medical rents today, as well as 90,000 square feet of land area.
The purchase of the property is made through the purchase of all shares in Mark & Schakt Fastigheter i Umeå AB. The seller is Mark & Schakt in Obbola AB. Date of access is October 31, 2021.
Photo of Ulf Hannelius, CEO, Diamyd Medical